Folate–chitosan nanoparticle delivery of cannabidiol for targeted triple-negative breast cancer therapy
Journal of Pharmacy and Pharmacology · 2025
DOI: 10.1093/jpp/rgaf072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Jia Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Agriculture and Biotechnology, Sun Yat-sen University, Shenzhen, Guangdong 518307, China. Hauptthemen laut MEDLINE: Chitosan, Triple Negative Breast Neoplasms, Folic Acid, Cannabidiol. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shenzhen.
Abstract (Originalsprache)
Objectives
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited treatment options. Cannabidiol (CBD) has demonstrated anticancer potential, but its clinical application is hindered by poor solubility and nonspecific distribution. This study aimed to develop a folic acid-modified chitosan (FA–CS) nanoparticle system to enhance the targeted delivery and therapeutic efficacy of CBD against TNBC.
Methods
FA–CS@CBD nanoparticles were synthesized and characterized for morphology, size distribution, zeta potential, and stability. Their in vitro anticancer effects were evaluated through cytotoxicity, cellular uptake, apoptosis, and reactive oxygen species (ROS) assays in 4T1 breast cancer cells. The in vivo antitumour efficacy and systemic toxicity were assessed using a TNBC mouse model. Key findings FA–CS@CBD nanoparticles exhibited uniform morphology, stable physicochemical properties, and efficient cellular uptake. Compared to free CBD, the nanoparticles significantly enhanced ROS production, induced apoptosis, and inhibited migration in 4T1 cells. In vivo studies demonstrated strong tumour-targeting capability and a tumour inhibition rate of 68.07%, with minimal systemic toxicity.
Conclusions
The FA–CS@CBD nanoparticle system improved the targeted delivery and therapeutic effects of CBD against TNBC while maintaining favorable biocompatibility. These findings highlight the potential of FA–CS-based nanocarriers for enhancing CBD clinical application in breast cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Agriculture and Biotechnology, Sun Yat-sen University, Shenzhen, Guangdong 518307, China.
- Shenzhen Zhongjia Bio-medical Technology Co., LTD, Shenzhen, Guangdong 518000, China.
- School of Pharmacy, Zunyi Medical University, Xinpu New District, Zunyi, Guizhou 563006, China.
- Department of Breast Oncology & State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Panyu District, Guangzhou, Guangdong 51000…
ORCID-Profile: Chengyu Huang
Förderung
- National Natural Science Foundation of China
- Shenzhen
Zitieren
APA
Liu, J., Wang, Y., Xie, L., Xiao, S., Zhang, X., Li, W., Peng, Y., Cai, R., Qu, S., & Huang, C. (2025). Folate–chitosan nanoparticle delivery of cannabidiol for targeted triple-negative breast cancer therapy. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf072
Vancouver
Liu J, Wang Y, Xie L, Xiao S, Zhang X, Li W, et al. Folate–chitosan nanoparticle delivery of cannabidiol for targeted triple-negative breast cancer therapy. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgaf072
BibTeX
@article{Liu2025,
author = {Liu, Jia and Wang, Yuqian and Xie, Lingfeng and Xiao, Shanghua and Zhang, Xueyan and Li, Wendi and Peng, Yutao and Cai, Ruizhao and Qu, Shoukang and Huang, Chengyu},
title = {Folate–chitosan nanoparticle delivery of cannabidiol for targeted triple-negative breast cancer therapy},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
doi = {10.1093/jpp/rgaf072}
}
EUVIMED